Company Overview and News

0
CVLT / CommVault Systems, Inc. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us2041661024_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) COMMVAULT SYSTEMS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 204166102 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover
CVLT

0
CVLT / CommVault Systems, Inc. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us2041661024_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) COMMVAULT SYSTEMS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 204166102 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover
CVLT

0
0
CVLT / CommVault Systems, Inc. DEF 14A

2018-07-03 sec.gov
Document UNITED STATES
CVLT

0
Commvault Systems (CVLT) Q4 2018 Results - Earnings Call Transcript

2018-05-01 seekingalpha
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Fiscal Year Fourth Quarter Commvault Earnings Conference Call. At this time, all participants are in a listen-only mode to prevent background noise. We will have a question-and-answer session later and the instructions will follow at that time. And as a reminder, this call is being recorded.
CVLT

0
CVLT / CommVault Systems, Inc. / Elliott Associates, L.P. - COMMVAULT SYSTEMS, INC. (Activist Investment)

2018-05-01 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CVLT

5
CVLT / CommVault Systems, Inc. / Elliott Associates, L.P. - COMMVAULT SYSTEMS, INC. (Activist Investment)

2018-05-01 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CVLT

0
BRIEF-Commvault Announces New Governance Initiatives To Support Strategic Transformation Plan

2018-05-01 reuters
* COMMVAULT SYSTEMS INC - BOARD TO FORM CEO SEARCH COMMITTEE, RETAIN LEADING EXECUTIVE SEARCH FIRM TO ASSIST IN LEADERSHIP SUCCESSION
CVLT

222
Venture Capital Deals Of The Week: Alibaba Invests $717M In Rural China

2018-04-21 seekingalpha
Rural China e-commerce: Alibaba (NYSE:BABA) invested $717M in Huitongda Network Co., an e-commerce platform that could expand the tech giant’s sales reach to rural areas. Other investors include Shunwei Capital, China Merchants Bank, and Jiangsu Govtor Capital. The funding brought
JD 3968 BABA DVMT MSFT CVLT NTNX

84
Buy These Cybersecurity Stocks and ETFs to Forget Your Tech Woes

2018-04-06 investorplace
Investors must be in two minds about investing in tech after such massive selloffs, but they should note that not all segments were badly hurt in the recent rout. The crash that was caused by reports of Facebook Inc (NASDAQ:FB) data breaches in mid-March, spread like wildfire in Wall Street, and particularly hurt the tech behemoths.
FB FEYE PANW CVLT AKAM FTNT

55
Forget Tech Woes: Buy These Cybersecurity Stocks & ETFs

2018-04-05 zacks
Investors must be in two minds about investing in tech after such massive selloffs, but they should note that not all segments were badly hurt in the recent rout. The crash that was caused by reports of Facebook FB data breaches in mid-March, spread like wildfire in Wall Street, and particularly hurt the tech behemoths.
FEYE VIRT PANW CVLT AKAM FTNT

128
Activist Investors Should Taker the Lead on Board Diversity - Bloomberg

2018-04-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BLK CDK ADPVV PLCM WIFI ADP DRI CVLT MITL QCOM MSCI CTSH

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

6h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 204166102